 Zacks Small-Cap Research has started coverage on drug developer Tiziana Life Sciences PLC NASDAQ:TLSA LON:TILS, which is advancing three candidates for a variety of indications in autoimmune disease, cancer and coronavirus COVID-19. Zacks has placed a valuation of US7.50 per ADR share compared to a current price of US3 in New York up over 12 on the day. 